FDA grants second orphan drug designation to Hutchmed's sovleplenib, this time for AIHA
The November 5, 2026 designation covers autoimmune hemolytic anemia, weeks after a similar designation for immune thrombocytopenia.
SEC filing (2)
8 stories
The November 5, 2026 designation covers autoimmune hemolytic anemia, weeks after a similar designation for immune thrombocytopenia.
SEC filing (2)
The regulatory filings follow an FDA submission in September 2026 and build on SAFFRON Phase III data showing a 45% cut in progression risk and nearly five months of added survival.
SEC filing (3)
The licensing agreement covering the KRAS-EGFR antibody conjugate candidate took effect after antitrust clearance, triggering a $110 million upfront payment.
SEC filing
The application, based on the Phase III SAFFRON trial, targets patients who progressed on EGFR-TKI therapy with MET overexpression or amplification.
SEC filing (2)
HUTCHMED will get $110 million upfront as GSK takes global rights outside Greater China to the KRAS-EGFR conjugate HMPL-A830, with milestone figures stated differently across the filing.
SEC filing